Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 8, 2013

Threshold begins Phase II trial of investigational hypoxia-targeted drug

Threshold Pharmaceuticals has startedd Phase II trial to assess the clinical efficacy and safety of investigational hypoxia-targeted drug, TH-302, to treat patients with melanoma.

metastatic_melanoma

Threshold Pharmaceuticals has startedd Phase II trial to assess the clinical efficacy and safety of investigational hypoxia-targeted drug, TH-302, to treat patients with melanoma.

A range of biomarkers will also be assessed in the study such as serum, tumour biopsy, and PET imaging hypoxia biomarkers useful in predicting treatment outcomes and associated with tumour response to TH-302 therapy.

University of Toronto assistant professor Anthony Joshua said hypoxia is believed to be an important therapeutic target for patients with metastatic melanoma.

"Targeting hypoxic melanoma cells may help in slowing tumour progression and treatment resistance and has the potential to be an adjunct to current therapies," Joshua said.

Merck, Threshold’s partner for the development of TH-302, will fund 70% of development costs of the single-arm, multi-centre study.

"Targeting hypoxic melanoma cells may help in slowing tumour progression and treatment resistance and has the potential to be an adjunct to current therapies."

Around 40 patients with advanced melanoma will be administered with 480mg/m² TH-302 per week on a 28-day cycle.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The primary endpoint is three-month progression-free survival, while secondary endpoints are response rate, duration of response, overall survival, safety and evaluation of potential imaging, serum, and tissue biomarkers associated with tumour response and predict for efficacy and safety of TH-302 therapy.

Threshold chief medical officer Dr Tillman Pearce said: "This Phase 2 study holds strategic importance for the overall TH-302 development program in potentially broadening therapeutic applications for TH-302 as well as facilitating potentially important biomarker research."

An increased potential for invasiveness, metastasis, and treatment resistance is exhibited by the cells in the hypoxic regions. Hypoxia may also suppress the immune response to cancer.


Image: Lymph node with almost complete replacement by metastatic melanoma. Photo: courtesy of Gabriel Caponetti, MD.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU